LAKEMEDELSVERKET

Their core work

Läkemedelsverket is Sweden's national regulatory authority for medicines, medical devices, and narcotic drugs — a government agency responsible for approving, monitoring, and ensuring the safety of medicinal products on the Swedish market. In EU research projects, they contribute official regulatory expertise, national authority perspectives, and direct experience implementing EU pharmaceutical law at the national level. Their H2020 work focuses specifically on digital medicine data infrastructure: standardizing how medicines are identified and described across EU member states, and enabling safe cross-border exchange of health data. They are one of the few national medicines agencies actively engaged in building the technical and regulatory standards that underpin Europe's pharmaceutical digital transformation.

What they specialise in

How they've shifted over time

MPA entered H2020 in 2019 with a dual focus: first, supporting the academic pipeline for regulatory science through STARS — essentially investing in the next generation of regulatory professionals. Simultaneously, they joined UNICOM, which represents a significant pivot toward digital infrastructure for medicines data, specifically IDMP standardization and cross-border eHealth interoperability. Both projects launched the same year, so the keyword shift from "regulation / regulatory science" to "IDMP / drug database / CEF / pharmacovigilance" reflects a deepening into the technical implementation layer of digital pharmaceutical regulation rather than a change in direction. The trajectory points toward data standardization and digital regulatory infrastructure as their dominant EU engagement area.

MPA is moving toward becoming a key national implementer of EU digital medicine identification standards — future collaborators working on pharmaceutical data interoperability, eHealth infrastructure, or cross-border medicine safety systems will find them a highly relevant partner.

How they like to work

MPA participates exclusively as a consortium partner, never as coordinator — consistent with national regulatory authorities who bring official mandate and domain authority rather than project management capacity. Their presence in consortia with 51 unique partners across 22 countries suggests they join large, multi-stakeholder EU-level projects rather than small bilateral efforts. Working with them means access to a national competent authority perspective and legitimacy that few other partner types can provide, but they are unlikely to drive project administration.

MPA has built a network of 51 unique partners across 22 countries through just 2 projects — indicating participation in large, geographically diverse consortia rather than niche partnerships. Their network almost certainly includes other EU national medicines agencies, EMA, and major pharmaceutical data infrastructure actors.

What sets them apart

As a national medicines regulatory authority, MPA occupies a position that academic institutions and private companies cannot replicate: they bring legal mandate, official implementation experience, and direct links to EMA and the EU regulatory network. For any consortium working on pharmaceutical data standards, eHealth interoperability, or regulatory science, having a national competent authority as partner significantly strengthens credibility with funders and end-users. Among EU member state medicines agencies, Sweden's MPA is among the more digitally active, making them a particularly useful partner for projects bridging regulation and digital health infrastructure.

Highlights from their portfolio

• UNICOM
  The flagship engagement — a 5-year, nearly €1M project to implement ISO IDMP medicine identification standards across EU member states, connecting national regulatory systems with EMA and the CEF eHealth backbone.
• STARS
  Reflects MPA's investment in the regulatory science talent pipeline, an unusual move for an operational authority that signals long-term commitment to the EU regulatory science community.